Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pp65-flLAMP mRNA dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Immunomic Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
The pp65-flLAMP mRNA dendritic cell vaccine is an investigational autologous cell-based immunotherapy designed to treat glioblastoma and other high-grade gliomas. It consists of a patient's own dendritic cells (DCs) that have been pulsed with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 fused to the full-length lysosomal-associated membrane protein (flLAMP). The flLAMP component is specifically designed to direct the pp65 antigen to the lysosomal compartment, thereby enhancing MHC class II presentation and stimulating a robust CD4+ T-cell response alongside CD8+ T-cell activation. Since CMV pp65 is highly expressed in glioblastoma cells but absent in normal brain tissue, the vaccine aims to induce a targeted cytotoxic T-lymphocyte response against the tumor. Developed primarily at Duke University, it is often administered with GM-CSF and site preconditioning with tetanus-diphtheria toxoid.
- Other names
- CMV-pp65-flLAMP mRNA-loaded dendritic cell vaccineCMV-pp-65-flLAMP mRNA-loaded dendritic cell vaccineCMV-pp 65-flLAMP mRNA-loaded dendritic cell vaccinepp65-flLAMP mRNA DC vaccinepp-65-flLAMP mRNA DC vaccinepp 65-flLAMP mRNA DC vaccine
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on pp65-flLAMP mRNA dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pp65-flLAMP mRNA dendritic cell vaccine.